BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Talima Therapeutics, Inc. Hires New CEO


1/16/2008 8:43:30 AM

SAN CARLOS, Calif., Jan. 15, 2008 (PRIME NEWSWIRE) -- Talima Therapeutics, a drug delivery company located in San Carlos California, announced that it has recruited Martin Babler to assume the position of President and Chief Executive Officer. The company has developed a patented drug delivery technology that can be used to treat a variety of conditions.

``Martin brings to Talima the ideal combination of skills and successful experiences that will help guide the company as we pursue regulatory approval for Talima's breakthrough drug delivery technology,'' said board member and investor Fred Dotzler of De Novo Ventures.

Most recently, Martin was a senior executive at Genentech where he served in various management positions for the past eight years. While Vice President of Immunology Sales and marketing, he oversaw successful launches of both Xolair and Rituxan, and built and managed high-powered marketing and sales teams. Previously he was Senior Director of Commercial Development where he and his team of professionals, in close collaboration with R&D helped manage and prepare the Genentech product pipeline for successful launches.

Prior to Genentech, Mr. Babler worked at Eli Lilly and Company in various U.S. and international strategic positions in sales, marketing and business development. He is a graduate of the ETH in Zurich, Switzerland with a degree in Pharmaceutical Science.

``Martin was just the person we were looking for to lead the company toward commercialization of our existing product. His experience will also enable us to better exploit the potential of our technology,'' said founding CEO David Henkel-Wallace. ``When we started the company three years ago, we began outlining the characteristics of the person we would hire to take the company from proof-of-concept to commercialization. Martin meets all of those characteristics.''

About Talima:

Talima Therapeutics, a drug delivery company located in San Carlos California, has developed a breakthrough micro implant delivery technology for the localized application of small molecule drugs. The company's lead product is in phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the toenails. Enrollment of this phase I/II trial will continue for several months. Talima raised $19 million in Series B financing led by De Novo Ventures, US Venture Partners and Latterell Ventures in May 2007.

Contact: Talima Therapeutics Martin Babler 650 331 7246 mbabler@talima.com www.talima.com

Source: Talima Therapeutics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES